Alpha 2.0
Login Register
» Authors » B E Johnson

B E Johnson

Explore the profile of B E Johnson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 267
Citations 4827
Followers 0
Related Specialties
Oncology
Dermatology
General Medicine
Top 10 Co-Authors
D C Ihde
A F Gazdar
J Ferguson
M J Kelley
W FRAIN-BELL
J D Minna
R I Linnoila
S M Steinberg
J L Mulshine
N K Gibbs
Published In
Br J Dermatol
Cancer Res
J Natl Cancer Inst
J Clin Oncol
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2
Qiu X, Tarantino P, Li R, Grinshpun A, Gupta H, Hughes M, et al.
ESMO Open . 2025 Jan; 10(2):104111. PMID: 39826477
Background: The approval of trastuzumab deruxtecan has prompted the subgrouping of human epidermal growth factor receptor 2-negative (HER2-) breast cancers (BCs) to HER2 0 and HER2 low on the basis...
2.
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS inhibitors
Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper A, Ricciuti B, et al.
Ann Oncol . 2024 Dec; 36(3):297-308. PMID: 39637943
Background: Approximately 10% of lung adenocarcinomas (LUADs) have mucinous histology (LUAD), which is associated with a light/absent smoking history and a high prevalence of KRAS mutations. We sought to characterize...
3.
Lung cancer research and treatment: global perspectives and strategic calls to action
Meyer M, Peters S, Mok T, Lam S, Yang P, Aggarwal C, et al.
Ann Oncol . 2024 Oct; 35(12):1088-1104. PMID: 39413875
Background: Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to review the current landscape of lung cancer research and...
4.
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Di Federico A, Alden S, Smithy J, Ricciuti B, Alessi J, Wang X, et al.
Ann Oncol . 2024 Jul; 35(10):902-913. PMID: 38950679
Background: Programmed death receptor ligand 1 (PD-L1) tumor proportion score (TPS) and tumor mutational burden (TMB) are key predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in non-small-cell lung cancer...
5.
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
Bakouny Z, Labaki C, Bhalla S, Schmidt A, Steinharter J, Cocco J, et al.
Ann Oncol . 2022 Jun; 33(8):836-844. PMID: 35715285
Background: COVID-19 disproportionately impacted patients with cancer as a result of direct infection, and delays in diagnosis and therapy. Oncological clinical trials are resource-intensive endeavors that could be particularly susceptible...
6.
The oxidation of copper catalysts during ethylene epoxidation
Greiner M, Jones T, Johnson B, Rocha T, Wang Z, Armbruster M, et al.
Phys Chem Chem Phys . 2015 Sep; 17(38):25073-89. PMID: 26345450
The oxidation of copper catalysts during ethylene epoxidation was characterized using in situ photoemission spectroscopy and electron microscopy. Gas chromatography, proton-transfer reaction mass spectrometry and electron-ionization mass spectrometry were used...
7.
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer
Heymach J, Lockwood S, Herbst R, Johnson B, Ryan A
Ann Oncol . 2014 Jul; 25(10):1941-1948. PMID: 25057173
Background: ZODIAC was a randomized phase III study of second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) that evaluated the addition of vandetanib to docetaxel. The study...
8.
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy
Nishino M, Jackman D, DiPiro P, Hatabu H, Janne P, Johnson B
Clin Radiol . 2014 May; 69(8):841-8. PMID: 24857677
Aim: To revisit the presumed relationship between tumour diameter and volume in advanced non-small-cell lung cancer (NSCLC) patients, and determine whether the measured volume using volume-analysis software and its proportional...
9.
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer
Besse B, Heist R, Papadmitrakopoulou V, Camidge D, Beck J, Schmid P, et al.
Ann Oncol . 2013 Dec; 25(2):505-11. PMID: 24368401
Background: This phase Ib study aimed to establish the feasible everolimus dose given with standard-dose etoposide plus cisplatin (EP) for extensive-stage small-cell lung cancer (SCLC). Patients And Methods: An adaptive...
10.
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer
Besse B, Leighl N, Bennouna J, Papadimitrakopoulou V, Blais N, Traynor A, et al.
Ann Oncol . 2013 Dec; 25(2):409-15. PMID: 24368400
Background: Preclinical data suggest combining a mammalian target of rapamycin inhibitor with erlotinib could provide synergistic antitumor effects in advanced non-small-cell lung cancer (NSCLC). Patients And Methods: In this multicenter,...